Works matching Kipps: The Story of a Simple Soul: Analysis of Major Characters

Results: 72
    1
    2
    3
    4

    NOTES AND QUERIES.

    Published in:
    Wellsian, 2018, n. 41, p. 43
    By:
    • WELLS, H. G.
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect.

    Published in:
    Science Translational Medicine, 2020, v. 12, n. 561, p. 1, doi. 10.1126/scitranslmed.abb7661
    By:
    • Bachireddy, Pavan;
    • Ennis, Christina;
    • Nguyen, Vinhkhang N.;
    • Gohil, Satyen H.;
    • Clement, Kendell;
    • Shukla, Sachet A.;
    • Forman, Juliet;
    • Barkas, Nikolaos;
    • Freeman, Samuel;
    • Bavli, Natalie;
    • Elagina, Liudmila;
    • Leshchiner, Ignaty;
    • Mohammad, Arman W.;
    • Mathewson, Nathan D.;
    • Keskin, Derin B.;
    • Rassenti, Laura Z.;
    • Kipps, Thomas J.;
    • Brown, Jennifer R.;
    • Getz, Gad;
    • Ho, Vincent T.
    Publication type:
    Article
    15
    16
    17

    IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 106, doi. 10.1002/hon.69_2629
    By:
    • Wu, J.;
    • Bolen, C.;
    • Seymour, J.F.;
    • Hillmen, P.;
    • Eichhorst, B.;
    • Eldering, E.;
    • Kipps, T.J.;
    • Langerak, A.W.;
    • Mellink, C.;
    • Kevie‐Kersemaekers, A.F.;
    • Owen, C.;
    • Chyla, B.;
    • Punnoose, E.A.;
    • Wang, J.;
    • Boyer, M.;
    • Humphrey, K.;
    • Jiang, Y.;
    • Kater, A.P.
    Publication type:
    Article
    18

    IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 106, doi. 10.1002/hon.69_2629
    By:
    • Wu, J.;
    • Bolen, C.;
    • Seymour, J.F.;
    • Hillmen, P.;
    • Eichhorst, B.;
    • Eldering, E.;
    • Kipps, T.J.;
    • Langerak, A.W.;
    • Mellink, C.;
    • Kevie‐Kersemaekers, A.F.;
    • Owen, C.;
    • Chyla, B.;
    • Punnoose, E.A.;
    • Wang, J.;
    • Boyer, M.;
    • Humphrey, K.;
    • Jiang, Y.;
    • Kater, A.P.
    Publication type:
    Article
    19
    20
    21

    Telehealth-delivered cognitive rehabilitation for people with cognitive impairment as part of the post-COVID syndrome: protocol for a randomised controlled trial as part of the CICERO (Cognitive Impairment in Long COVID: Phenotyping and Rehabilitation) study

    Published in:
    Trials, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s13063-024-08554-3
    By:
    • Vanova, Martina;
    • Patel, Aysha Mohamed Rafik;
    • Scott, Iona;
    • Gilpin, Gina;
    • Manning, Emily N.;
    • Ash, Charlotte;
    • Wittenberg, Philippa;
    • Lim, Jason;
    • Hoare, Zoe;
    • Evans, Rachel;
    • Bray, Nathan;
    • Kipps, Christopher M.;
    • Devine, Ciara;
    • Ahmed, Saliha;
    • Dunne, Ross;
    • Koniotes, Anna;
    • Warren, Catherine;
    • Chan, Dennis;
    • Suarez-Gonzalez, Aida
    Publication type:
    Article
    22
    23
    24

    CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S316, doi. 10.1016/S2152-2650(21)01747-X
    By:
    • Burger, Jan;
    • Barr, Paul;
    • Owen, Carolyn;
    • Robak, Tadeusz;
    • Tedeschi, Alessandra;
    • Bairey, Osnat;
    • Hillmen, Peter;
    • Coutre, Steve;
    • Devereux, Stephen;
    • Grosicki, Sebastian;
    • McCarthy, Helen;
    • Li, Jianyong;
    • Offner, Fritz;
    • Moreno, Carol;
    • Dai, Sandra;
    • Szoke, Anita;
    • Dean, James P.;
    • Kipps, Thomas J.;
    • Ghia, Paolo
    Publication type:
    Article
    25
    26
    27
    28

    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 6, p. 1375, doi. 10.1080/10428194.2021.2020779
    By:
    • Burger, Jan A.;
    • Robak, Tadeusz;
    • Demirkan, Fatih;
    • Bairey, Osnat;
    • Moreno, Carol;
    • Simpson, David;
    • Munir, Talha;
    • Stevens, Don A.;
    • Dai, Sandra;
    • Cheung, Leo W. K.;
    • Kwei, Kevin;
    • Lal, Indu;
    • Hsu, Emily;
    • Kipps, Thomas J.;
    • Tedeschi, Alessandra
    Publication type:
    Article
    29
    30
    31
    32

    MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 239, doi. 10.1002/hon.3163_156
    By:
    • Kater, A. P.;
    • Harrup, R.;
    • Kipps, T. J.;
    • Eichhorst, B.;
    • Owen, C. J.;
    • Assouline, S.;
    • Lamanna, N.;
    • Robak, T.;
    • Serna, J. d. l.;
    • Jaeger, U.;
    • Cartron, G.;
    • Montillo, M.;
    • Mellink, C.;
    • Chyla, B.;
    • Thadani‐Mulero, M.;
    • Lefebure, M.;
    • Jiang, Y.;
    • Millen, R.;
    • Boyer, M.;
    • Seymour, J. F.
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.32_2879
    By:
    • Tam, C. S. L;
    • Allan, J. N;
    • Siddiqi, T;
    • Kipps, T. J;
    • Jacobs, R;
    • Opat, S;
    • Barr, P. M;
    • Tedeschi, A;
    • Trentin, L;
    • Bannerji, R;
    • Jackson, S;
    • Kuss, B;
    • Moreno, C;
    • Szafer‐Glusman, E;
    • Russell, K;
    • Zhou, C;
    • Ninomoto, J;
    • Dean, J. P;
    • Ghia, P;
    • Wierda, W. G
    Publication type:
    Article
    40

    INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 109, doi. 10.1002/hon.2437_99
    By:
    • Kipps, T.J.;
    • Fraser, G.;
    • Coutre, S.E.;
    • Brown, J.R.;
    • Barrientos, J.C.;
    • Barr, P.M.;
    • Byrd, J.C.;
    • O'Brien, S.M.;
    • Dilhuydy, M.;
    • Hillmen, P.;
    • Jaeger, U.;
    • Moreno, C.;
    • Cramer, P.;
    • Stilgenbauer, S.;
    • Chanan ‐ Khan, A.A.;
    • Mahler, M.;
    • Salman, M.;
    • Cheng, M.;
    • Londhe, A.;
    • Ninomoto, J.
    Publication type:
    Article
    41

    Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.

    Published in:
    British Journal of Haematology, 2016, v. 175, n. 5, p. 892, doi. 10.1111/bjh.14332
    By:
    • Mato, Anthony;
    • Nabhan, Chadi;
    • Kay, Neil E.;
    • Weiss, Mark A.;
    • Lamanna, Nicole;
    • Kipps, Thomas J.;
    • Grinblatt, David L.;
    • Flinn, Ian W.;
    • Kozloff, Mark F.;
    • Flowers, Christopher R.;
    • Farber, Charles M.;
    • Kiselev, Pavel;
    • Swern, Arlene S.;
    • Sullivan, Kristen;
    • Flick, E. Dawn;
    • Sharman, Jeff P.
    Publication type:
    Article
    42

    Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

    Published in:
    American Journal of Hematology, 2019, v. 94, n. 12, p. 1353, doi. 10.1002/ajh.25638
    By:
    • Munir, Talha;
    • Brown, Jennifer R.;
    • O'Brien, Susan;
    • Barrientos, Jacqueline C.;
    • Barr, Paul M.;
    • Reddy, Nishitha M.;
    • Coutre, Steven;
    • Tam, Constantine S.;
    • Mulligan, Stephen P.;
    • Jaeger, Ulrich;
    • Kipps, Thomas J.;
    • Moreno, Carol;
    • Montillo, Marco;
    • Burger, Jan A.;
    • Byrd, John C.;
    • Hillmen, Peter;
    • Dai, Sandra;
    • Szoke, Anita;
    • Dean, James P.;
    • Woyach, Jennifer A.
    Publication type:
    Article
    43

    Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

    Published in:
    American Journal of Hematology, 2019, v. 94, n. 5, p. 554, doi. 10.1002/ajh.25436
    By:
    • O'Brien, Susan M.;
    • Byrd, John C.;
    • Hillmen, Peter;
    • Coutre, Steven;
    • Brown, Jennifer R.;
    • Barr, Paul M.;
    • Barrientos, Jacqueline C.;
    • Devereux, Stephen;
    • Robak, Tadeusz;
    • Reddy, Nishitha M.;
    • Kipps, Thomas J.;
    • Tedeschi, Alessandra;
    • Cymbalista, Florence;
    • Ghia, Paolo;
    • Chang, Stephen;
    • Ninomoto, Joi;
    • James, Danelle F.;
    • Burger, Jan A.
    Publication type:
    Article
    44
    45

    Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-naïve CLL (RESONATE-2TM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S46, doi. 10.1016/j.clml.2016.07.066
    By:
    • Kipps, Thomas;
    • Ghia, Paolo;
    • Tedeschi, Alessandra;
    • Barr, Paul;
    • Robak, Tadeusz;
    • Owen, Carolyn;
    • Bairey, Osnat;
    • Hillmen, Peter;
    • Bartlett, Nancy;
    • Li, Jianyong;
    • Simpson, David;
    • Grosicki, Sebastian;
    • Deverux, Stephen;
    • McCarthy, Helen;
    • Coutre, Steven;
    • Offner, Fritz;
    • Moreno, Carol;
    • Zhou, Cathy;
    • Styles, Lori;
    • James, Danelle
    Publication type:
    Article
    46

    A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S44, doi. 10.1016/j.clml.2016.07.064
    By:
    • Choi, Michael;
    • Jamieson, Catriona;
    • Widhopf, George;
    • Yu, Jian;
    • Castro, Januario;
    • Kidwell, Reilly;
    • Li, Hongying;
    • Juarez, Tiffany;
    • Gorak, Susette;
    • Pittman, Emily;
    • Gutierrez, Charlene;
    • Rassenti, Laura;
    • Messer, Karen;
    • Prussak, Charles;
    • Kipps, Thomas
    Publication type:
    Article
    47

    Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S51, doi. 10.1016/j.clml.2016.07.074
    By:
    • Tam, Constantine;
    • Roberts, Andrew W.;
    • Ma, Shuo;
    • Brander, Danielle;
    • Kipps, Thomas J.;
    • Barrientos, Jacqueline C.;
    • Davids, Matthew S.;
    • Anderson, Mary Ann;
    • Choi, Michael;
    • Lash, Leanne;
    • Verdugo, Maria;
    • Kim, Su Young;
    • Zhu, Ming;
    • Seymour, John F.
    Publication type:
    Article
    48
    49
    50